After a decade of using a novel approach to select patients for laryngeal cancer treatment, researchers are reporting "exceptional" survival rates nearing 80 percent, even for the most advanced patients.
Cervical cancer is a preventable disease if detected on time, but it remains one of the leading causes of cancer deaths among women in Latin America, particularly women of poor and indigenous communities.
Nearly half of women treated for early stage breast cancer reported at least one side effect from their treatment that was severe or very severe, a new study finds.
A protein thought to fuel pancreatic cancer development plays a much more complicated role, a new study finds. PDX1 is critical for cancer growth, but blocking it may lead to more aggressive tumors.
Recognizing a critical need to improve national vaccination rates for the human papillomavirus, the University of Michigan Comprehensive Cancer Center has again united with each of the 69 National Cancer Institute-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention.
As some national guidelines now recommend against routine prostate cancer screening, the overall rate of men receiving treatment for the disease declined 42 percent, a new study finds.
Researchers at the University of Michigan have had initial success in mice using nanodiscs to deliver a customized therapeutic vaccine for the treatment of colon and melanoma cancer tumors.
By developing a new mouse model to study a poorly understood protein, researchers uncovered its link to metaplastic breast cancer, opening the door to better understanding of this challenging breast cancer subtype.
Nearly half of early stage breast cancer patients considered having double mastectomy and one in six received it – including many who were at low risk of developing a second breast cancer, a new study finds.
Researchers found that patients whose oropharyngeal cancer recurred had higher levels of antibodies for two proteins, E6 and E7, which are found in HPV-fueled cancers. The finding suggests a potential blood-based marker that could predict when cancer is likely to return.